Source-grounded facts extracted from EXELIXIS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
EXELIXIS, INC. shareholders approved Advisory approval of executive compensation (Say on Pay) at the 2026-05-26 meeting.
“4. Approval, on an advisory basis, of the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement (Say on Pay): Exelixis stockholders approved the Say on Pay proposal. FOR AGAINST ABSTAIN BROKER NON-VOTES 163,104,135 43,156,553 329,618 22,436,080”
EXELIXIS, INC. shareholders approved Approval of the 2017 Plan at the 2026-05-26 meeting.
“3. Approval of the 2017 Plan: Exelixis stockholders approved the 2017 Plan. FOR AGAINST ABSTAIN BROKER NON-VOTES 196,926,657 9,343,837 319,812 22,436,080”
EXELIXIS, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-26 meeting.
“2. Ratification of Ernst & Young LLP as Exelixis’ independent registered public accounting firm: Exelixis stockholders ratified the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 1, 2027. FOR AGAINST ABSTAIN BROKER NON-VOTES 222,343,120 6,485,691 197,575 —”
EXELIXIS, INC. shareholders approved Election of 11 directors at the 2026-05-26 meeting.
“1. Election of Directors: Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2027, and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal: FOR AGAINST ABSTAIN BROKER NON-VOTES Mary C. Beckerle, Ph.D. 204,854,581 1,538,523 197,202 22,436,080 S. Gail Eckhardt, M.D. 205,409,482 1,022,879 157,945 22,436,080 Maria C. Freire, Ph.D. 180,367,648 26,067,310 155,348 22,436,080 Tomas J. Heyman 200,508,205 5,902,008 180,093 22,436,080 David E. Johnson 205,319,312 1,096,455 174,539 22,436,080 Michael M. Morrissey, Ph.D. 204,731,180 1,692,296 166,830 22,436,080 Robert L. Oliver, Jr. 205,297,039 1,137,865 155,402 22,436,080 Stelios Papadopoulos, Ph.D. 198,500,120 7,922,275 167,911 22,436,080 George Poste, DVM, Ph.D., FRS 204,405,453 2,023,314 161,539 22,436,080 Julie Anne Smith 202,976,810 3,456,942 156,554 22,436,080 Jack L. Wyszomierski 201,891,192 4,536,760 162,354 22,436,080”
EXELIXIS, INC. reported first quarter of 2026 results: revenue $610.8 million, net income $210.5 million, EPS $0.79 per share, diluted.
“& Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program”
EXELIXIS, INC. reported First Quarter 2024 results: revenue $425 million, EPS $0.12.
“Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 -”
Jacqueline Wright departed as Director at EXELIXIS, INC..
“On March 27, 2024, Jacqueline Wright notified Exelixis, Inc. (“the Company”) of her decision not to stand for re-election to the Board of Directors of the Company”
EXELIXIS, INC. reported financial results for quarter and year ended December 31, 2023.
“On February 6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended December 29, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.”
EXELIXIS, INC. updated its fiscal year ended December 29, 2023 guidance (initiated).
“On January 7, 2024, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended December 29, 2023, providing financial guidance for the fiscal year ending January 3, 2025, and delivered an update on its business.”
EXELIXIS, INC. announced a restructuring with charges of $25 million (approximately 175 employees or 13% of our total headcount at the end of 2023).
“On January 5, 2024, the Company’s Board of Directors (the Board) authorized a restructuring plan (the Plan) to reduce its workforce and rebalance the Company’s cost structure in alignment with its strategic priorities, including reducing real estate commitments and costs and terminating certain licensing partnerships. In connection with the Plan, the Company currently estimates that it will incur aggregate charges of approximately $25 million, $13.5 million of which relate to the workforce reduction. The Company expects these costs will be substantially recognized during the first quarter of 2024. The Plan will result in a workforce reduction of approximately 175 employees or 13% of our total headcount at the end of 2023.”
Alan M. Garber departed as Director at EXELIXIS, INC..
“Alan M. Garber, M.D., Ph.D., informed the Company that he has decided not to stand for re-election to the Board when his term expires at the 2024 annual meeting of stockholders.”
S. Gail Eckhardt was appointed as Director at EXELIXIS, INC..
“the Board increased the size of the Board to 13 members and appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to the Board to fill the newly created vacancies, effective immediately.”
Mary C. Beckerle was appointed as Director at EXELIXIS, INC..
“the Board increased the size of the Board to 13 members and appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to the Board to fill the newly created vacancies, effective immediately.”
EXELIXIS, INC.: Amended and restated Bylaws to update procedural requirements for director nominations, reflect universal proxy rules, revise advance notice deadlines, and make technical changes (effective 2023-12-14).
“On and effective as of December 14, 2023, the Board amended and restated the Company’s Bylaws (the “Revised Bylaws”) to, among other changes: i. Update and expand the procedural and informational requirements for director nominations and other proposals submitted by stockholders under the Company’s “advance notice” provisions, including updates to reflect the SEC’s adoption of “universal proxy” rules as set forth in Rule 14a-19 under the Securities Exchange Act of 1934, as amended;”
EXELIXIS, INC. reported quarter ended September 30, 2023 results: revenue $471.9 million, net income $1.0 million, or $0.00 per share, basic and diluted.
“Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -”
Vicki L. Goodman departed as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer at EXELIXIS, INC..
“Vicki L. Goodman, M.D., concluded her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of the Company, effective as of August 23, 2023.”
Vicki L. Goodman departed as Chief Medical Officer at EXELIXIS, INC..
“Effective August 23, 2023, Vicki L. Goodman, M.D., will conclude her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of Exelixis, Inc.”
EXELIXIS, INC. reported the quarter ended June 30, 2023 results: revenue Total revenues of $469.8 million, net income GAAP net income of $81.2 million, or $0.25 per share, EPS $0.25 per share.
“Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31”
EXELIXIS, INC. shareholders approved Approval, on an advisory basis, of the preferred frequency of shareholder advisory votes on the compensation of Exelixis’ named executive officers at the 2023-05-31 meeting.
“Exelixis stockholders approved the option of “1 Year” on the Say-on-Pay Frequency proposal. 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 250,754,219 262,732 5,363,172 436,254 —”
EXELIXIS, INC. shareholders approved Approval, on an advisory basis, of the compensation of Exelixis’ named executive officers, as disclosed in the proxy statement at the 2023-05-31 meeting.
“Exelixis stockholders approved the Say-on-Pay proposal. FOR AGAINST ABSTAIN BROKER NON-VOTES 212,824,174 42,820,366 1,171,837 —”
EXELIXIS, INC. shareholders approved Ratification of Ernst & Young LLP as Exelixis’ independent registered public accounting firm at the 2023-05-31 meeting.
“Exelixis stockholders ratified the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 29, 2023. FOR AGAINST ABSTAIN BROKER NON-VOTES 249,569,509 6,356,215 890,653 —”
EXELIXIS, INC. shareholders approved Election of Directors at the 2023-05-31 meeting.
“Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2024, and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal: FOR AGAINST BROKER NON-VOTES Maria C. Freire, Ph.D. 226,878,512 29,841,878 — Alan M. Garber, M.D., Ph.D. 221,687,200 35,031,720 — Tomas J. Heyman 209,404,239 47,310,782 — David E. Johnson 240,036,765 16,677,682 — Michael M. Morrissey, Ph.D. 225,102,450 31,469,654 — Robert L. Oliver, Jr. 250,850,361 5,869,649 — Stelios Papadopoulos, Ph.D. 223,062,261 33,656,523 — George Poste, DVM, Ph.D., FRS 225,550,366 31,169,483 — Julie Anne Smith 226,279,193 30,441,104 — Jacqueline Wright 226,507,736 30,212,275 — Jack L. Wyszomierski 223,003,412 33,711,474 —”
EXELIXIS, INC. reported First Quarter 2023 results: revenue $408.8 million, EPS GAAP Diluted EPS of $0.12.
“Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -”
Lance Willsey resigned as Director at EXELIXIS, INC..
“On May 7, 2023, the Board of Directors (the “Board”) of Exelixis, Inc. (the “Company”) announced that Dr. Lance Willsey was resigning from the Board effective immediately”
EXELIXIS, INC. reported the year ended December 31, 2022 results: revenue $1,611.1 million, net income $182.3 million, EPS $0.56 per share, diluted.
“Total revenues for the quarter and year ended December 31, 2022 were $423.9 million and $1,611.1 million, respectively, as compared to $451.1 million and $1,435.0 million for the comparable periods in 2021. Total revenues for the quarter and year ended December 31, 2022 included net product revenues of $377.4 million and $1,401.2 million, respectively, as compared to $302.7 million and $1,077.3 million for the comparable periods in 2021. The increases in net product revenues were primarily due to increases in sales volume, which were partially offset by higher discounts and allowances, driven primarily by chargebacks related to the 340B Drug Pricing Program. Collaboration revenues, composed of license revenues and collaboration services revenues, were $46.5 million and $209.8 million for the quarter and year ended December 31, 2022, respectively, as compared to $148.5 million and $357.7 million for the comparable periods in 2021. The decreases in collaboration revenues were primarily r”
EXELIXIS, INC. reported the quarter ended December 31, 2022 results: revenue $423.9 million, net income $(30.2) million, EPS $(0.09) per share, basic and diluted.
“Total revenues for the quarter and year ended December 31, 2022 were $423.9 million and $1,611.1 million, respectively, as compared to $451.1 million and $1,435.0 million for the comparable periods in 2021. Total revenues for the quarter and year ended December 31, 2022 included net product revenues of $377.4 million and $1,401.2 million, respectively, as compared to $302.7 million and $1,077.3 million for the comparable periods in 2021. The increases in net product revenues were primarily due to increases in sales volume, which were partially offset by higher discounts and allowances, driven primarily by chargebacks related to the 340B Drug Pricing Program. Collaboration revenues, composed of license revenues and collaboration services revenues, were $46.5 million and $209.8 million for the quarter and year ended December 31, 2022, respectively, as compared to $148.5 million and $357.7 million for the comparable periods in 2021. The decreases in collaboration revenues were primarily r”
EXELIXIS, INC. updated its the quarter and full year ended December 30, 2022 guidance (initiated).
“On January 8, 2023, Exelixis, Inc. (“Exelixis”) issued a press release announcing its preliminary unaudited financial results for the quarter and full year ended December 30, 2022, providing financial guidance for the full year ending December 29, 2023”
Dana T. Aftab was appointed as Chief Scientific Officer at EXELIXIS, INC..
“Dana T. Aftab, Ph.D., will become the Company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research.”
Peter Lamb changed role as Executive Vice President, Scientific Strategy at EXELIXIS, INC..
“Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, Inc. (“Exelixis” or the “Company”), will transition into a new role as Executive Vice President, Scientific Strategy, effective as of today.”
EXELIXIS, INC. reported the quarter ended September 30, 2022 results: revenue $411.7 million, net income $73.2 million, EPS $0.23.
“EXELIXIS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million - - GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 -”
Charles Cohen resigned as Director at EXELIXIS, INC..
“On April 11, 2022, Charles Cohen, Ph.D. notified Exelixis, Inc. (“Exelixis”) of his decision not to stand for re-election to the Board of Directors of Exelixis (the “Board”) at the 2022 annual meeting of stockholders of Exelixis (the “Annual Meeting”) and resign from the Board effective as of the Annual Meeting.”
Jacky Wright was appointed as Director at EXELIXIS, INC..
“the Board increased the size of the Board to 12 members and appointed Jacky Wright to the Board to fill the newly created vacancy.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.